JP2007000750A - 活性酸素消去剤、及び活性酸素消去剤の製造方法 - Google Patents
活性酸素消去剤、及び活性酸素消去剤の製造方法 Download PDFInfo
- Publication number
- JP2007000750A JP2007000750A JP2005182792A JP2005182792A JP2007000750A JP 2007000750 A JP2007000750 A JP 2007000750A JP 2005182792 A JP2005182792 A JP 2005182792A JP 2005182792 A JP2005182792 A JP 2005182792A JP 2007000750 A JP2007000750 A JP 2007000750A
- Authority
- JP
- Japan
- Prior art keywords
- active oxygen
- water
- oxygen scavenger
- ros
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052760 oxygen Inorganic materials 0.000 title claims abstract description 37
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 239000001301 oxygen Substances 0.000 title claims abstract description 36
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 64
- 229940123973 Oxygen scavenger Drugs 0.000 claims description 24
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000011084 recovery Methods 0.000 claims description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract description 24
- 238000000034 method Methods 0.000 abstract description 9
- 230000008034 disappearance Effects 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 description 28
- 238000006722 reduction reaction Methods 0.000 description 16
- -1 alkoxy radical Chemical class 0.000 description 14
- 230000035622 drinking Effects 0.000 description 13
- 150000003254 radicals Chemical class 0.000 description 13
- 230000009467 reduction Effects 0.000 description 13
- 230000036542 oxidative stress Effects 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 230000008030 elimination Effects 0.000 description 7
- 238000003379 elimination reaction Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000005868 electrolysis reaction Methods 0.000 description 5
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000001362 electron spin resonance spectrum Methods 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000033116 oxidation-reduction process Effects 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical group [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 229920000557 Nafion® Polymers 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Water Treatment By Electricity Or Magnetism (AREA)
Abstract
【解決手段】 酸化還元電位が−1000mV〜−200mVで、かつ、pHが3〜7の水である活性酸素消去剤。
【選択図】なし
Description
O2+4H++4e−→2H2O (1)
O2+4−→O2 − (2)
(1) 皮膚の皺
(2) 白内障
(3) 関節炎
(4) 痴呆症
(5) 動脈硬化 動脈硬化には、アテローム硬化(粥状硬化)、中膜硬化、細動脈硬化の3つのタイプが有る。フリーラジカルやROSは、最も危険なアテローム硬化を助長していると謂われている。そして、動脈硬化が進むと、高血圧症、脳卒中、狭心症、心筋梗塞等の病気が発現する可能性が高くなる。
(6) 糖尿病 インシュリンの分泌が悪くなると、血糖をコントロール出来なくなる。この為、高血糖の状態になる。これが糖尿病(インシュリン依存型)である。フリーラジカルやROSは糖尿病の発病から合併症の進展にまで関っていると謂われている。
(7) 発ガン ROSはDNAを損傷すると謂われている。DNAが損傷すると、発ガンの可能性が指摘されている。
身体中には、生成されたROSの毒性を消滅させる機能が備わっていると謂われている。酵素やビタミン類はそのような機能を奏すると謂われている。
(1) pH
(2) ORP(酸化還元電位)
(3) 1,1-diphenyl-2-picrylhydrazyl(DPPH)還元能力
H2O2+2H++2e−→2H2O (3)
式(3)より、還元反応をスムースに進める為には、アルカリ性より酸性のpHが好都合であることが理解される。
ことを特徴とする活性酸素消去剤によって解決される。
ことを特徴とする活性酸素消去剤によって解決される。
ことを特徴とする活性酸素消去剤によって解決される。
ことを特徴とする活性酸素消去剤の製造方法によって得られる。
4 アノード電極
5,6 隔膜
7 カソード電極
9 カソード室
11 中間室
代 理 人 宇 高 克 己
Claims (8)
- 酸化還元電位が−1000mV〜−200mVで、かつ、pHが3〜7の水である
ことを特徴とする活性酸素消去剤。 - DPPHを消去する成分が0.001ミリmol/L以上含まれることを特徴とする請求項1の活性酸素消去剤。
- 溶存酸素濃度が2ppm以下であることを特徴とする請求項1又は請求項2の活性酸素消去剤。
- 生活習慣病を改善する剤であることを特徴とする請求項1〜請求項3いずれかの活性酸素消去剤。
- 皮膚特性を改善する剤であることを特徴とする請求項1〜請求項3いずれかの活性酸素消去剤。
- 疲労回復の剤であることを特徴とする請求項1〜請求項3いずれかの活性酸素消去剤。
- 活性酸素の消去に用いられる剤の製造方法であって、
電導度が50μS/cm以下で、かつ、溶存酸素濃度が2ppm以下の水を電解還元する
ことを特徴とする活性酸素消去剤の製造方法。 - 請求項1〜請求項6いずれかの活性酸素消去剤の製造方法であって、
電導度が50μS/cm以下で、かつ、溶存酸素濃度が2ppm以下の水を電解還元する
ことを特徴とする活性酸素消去剤の製造方法。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005182792A JP2007000750A (ja) | 2005-06-23 | 2005-06-23 | 活性酸素消去剤、及び活性酸素消去剤の製造方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005182792A JP2007000750A (ja) | 2005-06-23 | 2005-06-23 | 活性酸素消去剤、及び活性酸素消去剤の製造方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011123283A Division JP2011200864A (ja) | 2011-06-01 | 2011-06-01 | 血管老化防止用飲用水、及び血管老化防止用飲用水の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2007000750A true JP2007000750A (ja) | 2007-01-11 |
Family
ID=37686830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005182792A Pending JP2007000750A (ja) | 2005-06-23 | 2005-06-23 | 活性酸素消去剤、及び活性酸素消去剤の製造方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2007000750A (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013532661A (ja) * | 2010-07-22 | 2013-08-19 | リベン ファーマシューティカルズ インコーポレイテッド | 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法 |
| WO2014141649A1 (ja) * | 2013-03-14 | 2014-09-18 | 株式会社 クリア | 天然物抽出飲料の製造方法 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000033377A (ja) * | 1998-07-22 | 2000-02-02 | Mizu Kk | 還元性電解水 |
| JP2002136271A (ja) * | 2000-11-06 | 2002-05-14 | Yashiro Kogyo Kk | 食品添加物及びこれを添加した食品、飲料 |
| JP2002254078A (ja) * | 2001-02-28 | 2002-09-10 | Nippon Torimu:Kk | 電解還元水およびその製造方法 |
| JP2004229534A (ja) * | 2003-01-29 | 2004-08-19 | Yukio Hasebe | 加水分解卵殻膜含有飲料 |
| JP2005046771A (ja) * | 2003-07-30 | 2005-02-24 | Noboru Horiguchi | 還元性イオン水製造装置 |
| WO2005018653A1 (ja) * | 2003-08-26 | 2005-03-03 | Nihon Kefir Co., Ltd. | スキンケア用の内服組成物 |
| JP2005126384A (ja) * | 2003-10-24 | 2005-05-19 | Mizu Kk | 薬理機能水、およびその用途 |
-
2005
- 2005-06-23 JP JP2005182792A patent/JP2007000750A/ja active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000033377A (ja) * | 1998-07-22 | 2000-02-02 | Mizu Kk | 還元性電解水 |
| JP2002136271A (ja) * | 2000-11-06 | 2002-05-14 | Yashiro Kogyo Kk | 食品添加物及びこれを添加した食品、飲料 |
| JP2002254078A (ja) * | 2001-02-28 | 2002-09-10 | Nippon Torimu:Kk | 電解還元水およびその製造方法 |
| JP2004229534A (ja) * | 2003-01-29 | 2004-08-19 | Yukio Hasebe | 加水分解卵殻膜含有飲料 |
| JP2005046771A (ja) * | 2003-07-30 | 2005-02-24 | Noboru Horiguchi | 還元性イオン水製造装置 |
| WO2005018653A1 (ja) * | 2003-08-26 | 2005-03-03 | Nihon Kefir Co., Ltd. | スキンケア用の内服組成物 |
| JP2005126384A (ja) * | 2003-10-24 | 2005-05-19 | Mizu Kk | 薬理機能水、およびその用途 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013532661A (ja) * | 2010-07-22 | 2013-08-19 | リベン ファーマシューティカルズ インコーポレイテッド | 磁気双極子安定化溶液の使用を含む疾患を処置または改善する方法および行動を向上させる方法 |
| WO2014141649A1 (ja) * | 2013-03-14 | 2014-09-18 | 株式会社 クリア | 天然物抽出飲料の製造方法 |
| JP2014176341A (ja) * | 2013-03-14 | 2014-09-25 | Kuria:Kk | 天然物抽出飲料の製造方法 |
| US9801396B2 (en) | 2013-03-14 | 2017-10-31 | Tech Corporation Co., Ltd. | Production method for natural-extract beverage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1413555A1 (en) | Method for antioxidation and antioxidative functional water | |
| US8562860B2 (en) | Method for activating and stabilizing dissolved hydrogen in water | |
| US20050170011A1 (en) | Method of inhibiting oxidation, water capable of inhibiting oxidation and use thereof | |
| US20070148256A1 (en) | Pharmacologic-functioning water and usage of the same | |
| US6551492B2 (en) | Electrolyzed water of anode side and process for production thereof | |
| Sohal et al. | Biochemical correlates of longevity in two closely related rodent species | |
| JP5835599B2 (ja) | 酸性水電解槽及びその酸性水の利用方法 | |
| US20020179455A1 (en) | Aqueous electrolyzed solution of ascorbyl glucosamine and preparation process therefor | |
| JP4783466B2 (ja) | 薬理機能水、およびその用途 | |
| JP2007000750A (ja) | 活性酸素消去剤、及び活性酸素消去剤の製造方法 | |
| JP2011190276A (ja) | 薬理機能水、およびその用途 | |
| WO2010004699A1 (ja) | 口臭抑制剤及びその生成方法 | |
| JP2011200864A (ja) | 血管老化防止用飲用水、及び血管老化防止用飲用水の製造方法 | |
| WO2004076363A1 (ja) | 混合電解水の製造方法 | |
| JP3423698B2 (ja) | ビタミンc入りアルカリ性電解水 | |
| JP2007170912A (ja) | 食品の抗酸化活性測定方法と、食品の抗酸化活性測定システム | |
| JP2005021875A (ja) | 水の酸化還元電位を維持する方法 | |
| TWI270532B (en) | Method for antioxidation and antioxidative functional water | |
| JPH1160429A (ja) | 洗顔水の生成方法及び洗顔水の生成装置及び洗顔水 | |
| JP2000308891A (ja) | 二酸化炭素溶存還元水およびその製造法 | |
| JP2001079549A (ja) | 電解水の製造方法、陰極側電解生成水、電解助剤および水の電気分解装置 | |
| JP2007253131A (ja) | 抗酸化剤を含有する機能水 | |
| JP3932447B2 (ja) | 溶液中の含有成分濃度測定方法 | |
| JP2004089797A (ja) | 任意に硬度調製可能、且つ還元系で、抗酸化性の機能を有するミネラル水の製造法 | |
| KR20030086832A (ko) | 양극 전해수 및 그 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080319 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20090522 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110406 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110601 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111221 |